Nanotechnological medical devices and nanopharmaceuticals: The European regulatory framework and research needs

Journal of Nanoscience and Nanotechnology

Volumn 7, Issue 12, 2007, Pages 4618-4625

  Rickerby, D G ^a  

^a JOINT RESEARCH CENTRE   (Italy)

Author keywords

Medical Devices; Nanomedicine; Pharmaceuticals; Regulation; Toxicology

Indexed keywords

BIOLOGY; CONSUMER PROTECTION; DRUG PRODUCTS; HEALTH; HEALTH RISKS; MEDICAL APPLICATIONS; NANOPARTICLES; PARTICLE SIZE;

APPLICATIONS OF NANOTECHNOLOGIES; ENVIRONMENTAL RISKS; MEDICAL DEVICES; NANOPHARMACEUTICALS; REGULATION; REGULATORY FRAMEWORKS; TOXICOLOGY; TRANSPORT CHARACTERISTICS;

MEDICAL NANOTECHNOLOGY;

DRUG;

APPARATUS, EQUIPMENT AND SUPPLIES; ARTICLE; EUROPE; HUMAN; NANOTECHNOLOGY; RISK MANAGEMENT;

EQUIPMENT AND SUPPLIES; EUROPE; HUMANS; NANOTECHNOLOGY; PHARMACEUTICAL PREPARATIONS; RISK MANAGEMENT;

EID: 41649107718     PISSN: 15334880     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (55)

1. R. Felten and I. Hussla, Microsystem and nanotechnologies applied for health: A 15-year perspective, Gesellschaft für Technolo- gieförderung, Itzehoe (2000).
2. M. Oud and I. Malsch, Socioeconomic report on nanotechnology and smart materials for medical devices, Nanoforum (2003).
3. M. Bøgedal, M. Gleiche, J.-C. Guibert, H. Hoffschulz, S. Locatelli, I. Malsch, M. Morrison, C. Nicollet, and V. Wagner, Nanotechnology and its implications for the health of the EU citizen, Nanoforum (2003).
4. B. Roszek, W. H. de Jong, R. E. Geertsma, Nanotechnology in medical applications: State-of-the-art in materials and devices. RIVM Report 265001001, Bilthoven (2005).
5. Consultative Document: Need for a Legislative Framework for Human Tissue Engineering and Tissue Engineered Products, European Commission, DG Enterprise, Brussels (2002).
6. ESF Scientific Forward Look on Nanomedicine, European Science Foundation, Strasbourg (2005).
7. K. K. Jain, Drug Discovery Today 10, 1435 (2005).
8. Foresight, Making the Future Work for You, UK Foresight Programme, Health and Ageing Population Panels, Department of Trade and Industry, London (2000).
9. Directive 93/42/EEC on medical devices, Official Journal of the European Communities L 169, 1 (1993).
10. Directive 90/385/EEC on active implantable medical devices, Official Journal of the European Communities L 189, 17 (1990).
11. Directive 98/79/EC on in vitro diagnostic medical devices, Official Journal of the European Communities L331, 1 (1998).
12. N. Thumm, H. Steg, and C. Witelegg, The impact of single market regulation on innovation: Regulatory reform and experiences of firms in the medical device industry, EUR 19734 EN, IPTS, JRC Seville (2000).
13. Directive 2001/83/EC on the community code relating to medicinal products for human use, Official Journal of the European Communities L 311, 67 (2001).
14. Directive 2001/20/EC on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use, Official Journal of the European Communities L 121, 34 (2001).
15. Directive 2004/27/EC amending directive 2001/83/EC on the community code relating to medicinal products for human use, Official Journal of the European Communities L 136, 34 (2004).
16. Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use, CHMP/SWP/4447/00 draft, Committee for Medicinal Products for Human Use, European Medicines Agency, London (2005).
17. Concept Paper on Scientific Requirements for the Environmental Risk Assessment of Gene Therapy Medicinal Products, EMEA/CHMP/203831/2005, Committee for Medicinal Products for Human Use, European Medicines Agency, London (2005).
18. Guidelines on a Medical Devices Vigilance System, MEDDEV 2.12-1 rev 4, European Commission, DG Enterprise (2001).
19. Regulation (EEC) No 2309/93 laying down community procedures for the authorization and supervison of medicinal products for human and veterinary use and establishing a European Agency for the evaluation of medicinal products, Official Journal of the European Communities L214, 1 (1993).
20. Regulation (EC) No 540/95, laying down the arrangements for reporting suspected unexpected adverse reactions which are not serious, Official Journal of the European Communities L 55, 5-6 (1995).
21. Regulation (EC) No 726/2004, laying down community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, Official Journal of the European Union L 136/1, 1 (2004).
22. D. G. Rickerby, Regulatory issues in connection with nano-technological medical devices, International Conference on Nan-otechnology and Smart Materials for Medical Devices: From Medical Diagnostics to Therapy, Rome (2004).
23. W. H. de Jong, B. Roszek, and R. E. Geertsma, Nanotechnology in medical applications: Possible risks for human health, RIVM report 265001002, Bilthoven (2005).
24. P. H. M. Hoet, I. Brüske-Hohlfeld, and O. V. Salata, Journal of Nanobiotechnology 2, 12 (2004).
25. G. Oberdörster, E. Oberdõrster, and J. Oberdörster, Environmental Health Perspectives 113, 823 (2005).
26. G. Oberdõrster, A. Maynard, K. Donaldson, V. Castranova, J. Fitzpatrick, K. Ausman, J. Carter, B. Karn, W. Kreyling, David Lai, S. Olin, N. Monteiro-Riviere, D. Warheit, and H. Yang, Particle and Fibre Toxicology 2, 8 (2005).
27. K. Donaldson, L. Tran, L. A. Jimenez, R. Duffin, D. E. Newby, N. Mills, W. MacNee, and V. Stone, Particle and Fibre Toxicology 2, 10 (2005).
28. P. J. A. Borm and W. Kreyling, J. Nanosci. Nanotechnol. 4, 521 (2004).
29. R. N. Alyaudtin, A. Reichel, R. Lobenberg, P. Ramge, J. Kreuter, and D. J. Begley, Journal of Drug Targeting 9, 209 (2001).
30. U. Schroeder, P. Sommerfeld, S. Ulrich, and B. A. Sabel, Journal of Pharmaceutical Sciences 87, 1305 (1998).
31. A. Nel, T. Xia, L. Mädler, and N. Li, Science 311, 622 (2006).
32. P. P. Ahonen, A. Moisala, U. Tapper, D. P. Brown, J. K. Jokiniemi, and E. I. Kauppinen, Journal of Nanoparticle Research 4, 43 (2002).
33. P. M. Oliver, G. W. Watson, E. T. Kelsey, and S. C. Parker, Journal Materials Chemistry 7, 563 (1997).
34. A. S. Barnard, P. Zapol, and L. A. Curtiss, Journal of Chemical Theory and Computation 1, 107 (2005).
35. G. Oberdörster, Inhalation Toxicology 8, 73 (1996).
36. R. Dunford, A. Salinaro, L. Cai, N. Serpone, S. Horikoshi, H. Hidaka, and J. Knowland, FEBS Utters 418, 87 (1997).
37. P. J. McHugh and J. Knowland, Photochemistry and Photobiology 66, 276 (1997).
38. L. C. Renwick, K. Donaldson, and A. Clouter, Toxicology and Applied Pharmacology 172, 119 (2001).
39. L. C. Renwick, D. Brown, A. Clouter, and K. Donaldson, Occupational and Environmental Medicine 61, 442 (2004).
40. G. Oberdörster, Z. Sharp, V. Atudorei, A. Elder, R. Gelein, W. Kreyling, and C. Cox, Inhalation Toxicology 16, 437 (2004).
41. K. Donaldson, V. Stone, A. Clouter, L. Renwick, and W. MacNee, Philosophical Transactions of the Royal Society of London 358, 2741 (2000).
42. C. W. Lam, J. T. James, R. McCluskey, and R. L. Hunter, Toxicological Sciences 77, 126 (2004).
43. A. A. Shvedova, A. R. Murray, E. R. Kisin, D. Schwegler-Berry, V. E. Kagan, V. Z. Gandelsman, and V. Castranova, Free Radical Research 37, 97 (2003).
44. C. M. Sayes, J. D. Former, W. Guo, D. Lyon, A. M. Boyd, K. D. Ausman, Y. J. Tao, B. Sitharaman, L. J. Wilson, J. B. Hughes, J. L. West, and V. L. Colvin, Nano Letters 4, 1881 (2004).
45. Towards a European Strategy for Nanotechnology, Office for Official Publications of the European Communities, Luxembourg (2004).
46. Nanosciences and Nanotechnologies: An Action Plan for Europe 2005-2009, European Commission, Office for Official Publications of the European Communities, Luxembourg (2005).
47. Proposal for a Regulation Concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), COM(2003) 644 final, European Commission, Brussels (2003).
48. Directive 67/548/EEC on the approximation of laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances, Official Journal of the European Communities 196, 1 (1967).
49. Opinion on the Appropriateness of Existing Methodologies to Assess the Potential Risks Associated with Engineered and Adventitious Products of Nanotechnologies, SCENIHR/002/05, DG Health and Consumer Protection, Brussels (2005).
50. Nanoscience and Nanotechnologies: Opportunities and Uncertainties, RS Policy Document 19/04, The Royal Society, London (2004).
51. P. Martin (ed.), Proceedings of the Workshop on Nanotechnologies: A Preliminary Risk Assessment, European Commission, DG Health and Consumer Protection, Brussels (2004).
52. R. Tomellini and C. de Villepin (eds.), Proceedings of the Workshop: Research Needs on Nanoparticles, Office for Official Publications of the European Communities, Luxembourg (2005).
53. R. Moore, Nanotechnology and novel medical technology products - Overcoming regulatory and other challenges, International Conference on Nanotechnology and Smart Materials for Medical Devices: From Medical Diagnostics to Therapy, Rome (2004).
54. Communication from the Commission on the Precautionary Principle, COM (2000) 1 final, European Commission, Brussels (2000).
55. R. Haum, U. Petschow, M. Steinfeldt, and A. von Gleich, Nanotechnology and Regulation Within the Framework of the Precautionary Principle, Institute for Ecological Economy Research, Berlin (2004).